Collecting blood and tissue samples from patients with recurrent or metastatic prostate or bladder cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on collecting and analyzing blood and tissue samples from patients diagnosed with locally recurrent or metastatic prostate or bladder/urothelial cancer. The samples will be studied in the laboratory to identify new biomarkers, potential drug targets, and understand treatment resistance. Patients will undergo procedures for sample collection, including mutation mapping, DNA sequencing, and gene expression profiling. The goal is to enhance the understanding of these cancers and improve treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with localized and/or metastatic bladder/urothelial or prostate cancer who have disease in the primary organ, biopsy accessible bone metastases (collaborating radiologists will determine if bone metastasis is appropriate for biopsy) or soft tissue metastases are eligible; men and women without cancer are eligible to have blood or normal tissue collected if acquired as part of non-research procedures (e.g. transurethral resection of the prostate or bladder); in patients without malignancy, no additional tissue beyond that necessary for care will be procured
* Ability to adequately understand and give informed consent
* Local or metastatic disease to soft tissue or bone at sites accessible to biopsy with minimal risk of complications Or the ability to obtain tissue with minimal risk of complication from a surgical procedure being conducted as a part of another research study Or for standard of care purposes or patients who have archival tissue collected for research or standard of care who are willing to donate archival tissue for this study
* Alternatively, men and women without cancer or who are at risk of developing cancer are eligible to have blood or normal tissue collected if acquired; tissue will only be acquired as part of non-research procedures (e.g. transurethral resection of the prostate or bladder; in patients without malignancy, no additional tissue beyond that necessary for care will be procured
* Platelet count \> 50,000
* White blood cell (WBC) \> 1,500
* Hemoglobin (Hgb) \> 8.0
* International normalized ratio (INR) \< 1.5
* Partial thromboplastin time (PTT) \< 45
* No history of excessive unexplained bleeding from previous surgery

Exclusion Criteria:

* Patients unable to stop chronic anticoagulation with warfarin or Lovenox for less than 3 days
* Serious or uncontrolled infection
* Treatment with a vascular endothelial growth factor (VEGF) inhibitor (such as Avastin) within the past 28 days

Where it's running

• Fred Hutch/University of Washington Cancer Consortium
  Seattle, Washington, United States Recruiting

Study contacts

• Principal investigator: Robert B. Montgomery — Fred Hutch/University of Washington Cancer Consortium
• Study coordinator: Robert B. Montgomery
• Email: rbmontgo@uw.edu
• Phone: 206-598-0856

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Collecting blood samples to evaluate tests for early cancer detection

  This study is collecting blood and tissue samples from people with and without cancer to see if new tests can help detect cancer earlier.

  Recruiting at 619 sites Alliance for Clinical Trials in Oncology · Anchorage, Alaska and 750 other locations · NCT05334069

• Therapeutic plasma exchange plus enfortumab vedotin and pembrolizumab for bladder and upper urinary tract urothelial cancer

  This trial will test whether doing a therapeutic plasma exchange before giving enfortumab vedotin (an antibody‑drug conjugate) and pembrolizumab (an immune checkpoint inhibitor) helps people with metastatic or refractory urothelial (bladder or upper tract) cancer who have progressed on prior therapies.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07087860

• See if virtual informed consent methods help people decide to join cancer research

  This trial tests whether virtual human communicators and different consent messages can influence cancer patients’ understanding and willingness to participate in research.

  Recruiting Mayo Clinic · Jacksonville, Florida · NCT07805083

• AI-powered supportive care chatbot for young adult cancer survivors

  A chatbot driven by artificial intelligence is tested to help young adult cancer survivors manage symptoms and care needs after treatment.

  Recruiting University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07772596

• Telehealth pharmacist-led opioid education for cancer patients

  This pilot tests a telehealth group education session led by a palliative care pharmacist to help adults with cancer use opioids more safely and effectively.

  Recruiting Fred Hutchinson Cancer Center · Seattle, Washington · NCT07737314

• Mindfulness program to help with symptoms in chronic graft-versus-host disease

  A mindfulness-based program is being tested to see if it can reduce patient-reported symptoms for adults with chronic graft-versus-host disease after a stem cell transplant.

  Recruiting City of Hope Medical Center · Duarte, California · NCT07733141

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.